Tacrolim0.1%

Tacrolim is a calcineurin-inhibitor immunosuppressant with two distinct approved uses depending on formulation:

• Systemic (oral/IV) - FDA-approved: Prophylaxis of organ rejection in patients receiving allogeneic kidney, liver, or heart transplants, used in combination with other immunosuppressive agents (e.g., corticosteroids, mycophenolate mofetil, or as part of a calcineurin-inhibitor-based regimen).
• Topical (ointment) - FDA-approved, second-line: Short-term and intermittent long-term treatment of moderate-to-severe atopic dermatitis in patients who have not responded adequately to, or are intolerant of, other topical prescription therapies.
• Off-label uses (not FDA-approved, evidence-supported in guidelines/literature): Certain autoimmune and inflammatory conditions such as lupus nephritis, severe ulcerative colitis, and prevention/treatment of graft-versus-host disease after hematopoietic stem cell transplant, used under specialist supervision.

Systemic Tacrolim is always used in combination with other immunosuppressants and is not intended as monotherapy for transplant rejection prophylaxis.

Tacrolim is a macrolide-derived calcineurin inhibitor with potent immunosuppressive activity. It is structurally distinct from cyclosporine but shares a similar mechanism of T-cell suppression. It is used systemically to prevent rejection after solid organ transplantation and topically for atopic dermatitis when other treatments are inadequate.

Calcineurin inhibitor; immunosuppressant (systemic use); topical immunomodulator (topical use).

Tacrolimus binds to the intracellular protein FKBP-12 (FK-binding protein), forming a complex that inhibits calcineurin, a calcium-dependent phosphatase. This inhibition prevents dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NFAT), blocking transcription of interleukin-2 (IL-2) and other cytokines essential for T-lymphocyte activation and proliferation. The net effect is suppression of T-cell-mediated immune responses, reducing the risk of allograft rejection. Tacrolimus is metabolized primarily by hepatic and intestinal CYP3A4/5 enzymes, has a narrow therapeutic index, and requires therapeutic drug monitoring (trough blood levels) during systemic use.

Oral Tacrolim capsules/tablets should be taken consistently either with or without food, at the same time relative to meals each day, generally on an empty stomach (at least 1 hour before or 2-3 hours after meals) for optimal and consistent absorption, unless the physician advises otherwise. Extended-release formulations must be swallowed whole and not crushed, chewed, or opened. Avoid grapefruit or grapefruit juice. Topical ointment should be applied as a thin layer to affected skin only, with hands washed before and after application (unless hands are the treated area), and the area should not be covered with occlusive dressings.

Tacrolim is primarily metabolized by CYP3A4/5, making it highly susceptible to drug interactions:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, erythromycin, protease inhibitors): markedly increase Tacrolim blood levels, raising nephrotoxicity and neurotoxicity risk; dose reduction and closer monitoring required.
• CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's Wort): reduce Tacrolim levels, risking under-immunosuppression and graft rejection.
• Other nephrotoxic agents (aminoglycosides, amphotericin B, NSAIDs, cyclosporine): additive nephrotoxicity when combined with Tacrolim.
• Live/live-attenuated vaccines: avoid during Tacrolim therapy due to blunted immune response and infection risk.
• Potassium-sparing diuretics, ACE inhibitors, ARBs: increased risk of hyperkalemia when combined with Tacrolim.
• Grapefruit juice: inhibits intestinal CYP3A4, increasing Tacrolim absorption and blood levels; should be avoided.

Therapeutic drug monitoring is essential whenever interacting medications are started or stopped.

Boxed warning-level risks (systemic use): Increased susceptibility to infection (bacterial, viral, fungal, opportunistic) and increased risk of malignancy, particularly lymphoma and skin cancers, due to the degree of overall immunosuppression. Tacrolim may also cause nephrotoxicity and neurotoxicity, requiring regular monitoring of renal function and blood trough levels.

Common systemic side effects include:

• Tremor, headache, insomnia
• Hypertension
• Hyperglycemia and new-onset diabetes mellitus after transplant
• Hyperkalemia, hypomagnesemia
• Diarrhea, nausea, vomiting
• Nephrotoxicity (elevated creatinine)
• Peripheral edema

Serious/rare effects: Seizures, posterior reversible encephalopathy syndrome (PRES), QT prolongation, thrombotic microangiopathy, and (topical use) a boxed warning noting rare post-marketing reports of malignancy (skin cancer, lymphoma) with topical calcineurin inhibitors, although a causal relationship has not been established; topical use is intended as second-line, short-term/intermittent therapy.

Topical use commonly causes application-site burning, stinging, pruritus, and erythema, especially in the first days of treatment.

Tacrolim crosses the placenta and is present in breast milk. Use during pregnancy only if the potential benefit (e.g., maintaining a transplanted organ) justifies the potential risk to the fetus, as untreated organ rejection poses serious risk to both mother and fetus; pregnancy in transplant recipients on Tacrolim requires close specialist monitoring for pre-term birth, low birth weight, and neonatal hyperkalemia/renal function. Breastfeeding is generally not recommended during systemic Tacrolim therapy unless a physician determines the benefits outweigh the risks, given potential infant exposure via milk. For topical use, avoid application to the breast area during breastfeeding. Always consult the treating transplant physician or dermatologist before use in pregnancy or while breastfeeding.

Tacrolim should be used only under the supervision of physicians experienced in immunosuppressive therapy and management of transplant patients. Key precautions include:

• Regular monitoring of blood trough concentrations, renal function, blood pressure, blood glucose, and electrolytes (especially potassium and magnesium) is required during systemic therapy.
• Increased risk of infections (including opportunistic infections) and malignancy with long-term systemic immunosuppression - see Side Effects.
• Avoid live vaccines during treatment - see Interactions.
• Use cautiously in patients with hepatic or renal impairment; dose adjustment may be required.
• Avoid excessive sun/UV exposure and use sun protection, particularly with topical use, due to a boxed warning regarding rare reports of malignancy with topical calcineurin inhibitors.
• Do not switch between different Tacrolim brands or formulations without physician guidance, as this can alter blood levels and rejection risk.
• Not for use in immunocompromised patients or those with compromised skin barrier from viral infections (topical use, e.g., active herpes) without physician advice.

Overdose with Tacrolim may present as exaggerated adverse effects, including worsened nephrotoxicity, tremor, hypertension, or infection risk. There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact emergency services/a poison control center. General supportive measures and monitoring of renal function and blood levels are undertaken by treating physicians; Tacrolim is not significantly removed by dialysis due to high protein binding.

Store oral capsules/tablets at room temperature (below 30°C), protected from light and moisture. Injectable concentrate typically requires refrigeration prior to dilution - always follow the specific product label for the exact IV storage requirement. Topical ointment should be stored at room temperature (below 25-30°C). Keep out of reach of children.

Renal impairment: Use with caution; nephrotoxicity risk is heightened, and dose adjustment with close monitoring of renal function and trough levels is required.

Hepatic impairment: Dose reduction is typically needed in significant hepatic impairment due to reduced Tacrolim clearance.

Elderly: No specific dose adjustment is established beyond standard trough-level-guided dosing, but elderly transplant recipients may have increased susceptibility to infection and nephrotoxicity, warranting close monitoring.

Pediatric: Systemic Tacrolim is approved for prevention of organ rejection in pediatric transplant recipients; children often require higher weight-based doses than adults due to differences in metabolism, with dosing individualized by trough monitoring. Topical ointment 0.03% is approved for children 2 years and older with moderate-to-severe atopic dermatitis; safety in children under 2 years has not been established.

Calcineurin inhibitors; Immunosuppressants

Binds FKBP-12 to form a complex that inhibits calcineurin phosphatase, blocking NFAT-mediated transcription of IL-2 and other cytokines, thereby suppressing T-lymphocyte activation and proliferation.

C

Systemic Tacrolim is approved for prophylaxis of organ rejection in pediatric kidney, liver, and heart transplant recipients, with dosing individualized based on body weight and trough blood level monitoring; pediatric patients often require proportionally higher doses than adults due to faster clearance. Topical Tacrolim 0.03% ointment is approved for moderate-to-severe atopic dermatitis in children 2 years of age and older as second-line therapy; safety and efficacy in children below 2 years of age have not been established, and long-term continuous use in children should be avoided given the boxed warning on malignancy risk with topical calcineurin inhibitors.